AQP4 and neoplasm: In the future, understanding how tumor cells present AQP4 and interact with immune cells could enable the development of next-generation therapies that block the initial priming of autoreactive lymphocytes, potentially preventing the neurological syndrome entirely without requiring broad immunosuppression.